ClinVar Miner

Submissions for variant NM_002439.5(MSH3):c.2674A>G (p.Met892Val)

gnomAD frequency: 0.00003  dbSNP: rs773713925
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001052256 SCV001216458 uncertain significance not provided 2025-01-07 criteria provided, single submitter clinical testing This sequence change replaces methionine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 892 of the MSH3 protein (p.Met892Val). This variant is present in population databases (rs773713925, gnomAD 0.007%). This missense change has been observed in individual(s) with colon cancer (PMID: 29212164). ClinVar contains an entry for this variant (Variation ID: 848488). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002429649 SCV002741316 uncertain significance Hereditary cancer-predisposing syndrome 2024-08-19 criteria provided, single submitter clinical testing The p.M892V variant (also known as c.2674A>G), located in coding exon 20 of the MSH3 gene, results from an A to G substitution at nucleotide position 2674. The methionine at codon 892 is replaced by valine, an amino acid with highly similar properties. This alteration was reported in an individual with colorectal cancer diagnosed at age 74 and two first degree relatives who were also diagnosed with colon cancer (Raskin L et al. Oncotarget, 2017 Nov;8:93450-93463). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear.
Baylor Genetics RCV004570191 SCV005054789 uncertain significance Endometrial carcinoma 2023-11-22 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV005036343 SCV005666210 uncertain significance Endometrial carcinoma; Familial adenomatous polyposis 4 2024-06-12 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.